COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab

被引：0
|
作者：
Anne H. Cross
Silvia Delgado
Mario Habek
Maria Davydovskaya
Brian J. Ward
Bruce A. C. Cree
Natalia Totolyan
Ratnakar Pingili
Linda Mancione
Xixi Hu
Roseanne Sullivan
Wendy Su
Ronald Zielman
Ayan Das Gupta
Xavier Montalban
Kevin Winthrop
机构：
[1] Washington University,Department of Neurology
[2] University of Miami Miller School of Medicine,Infectious Diseases Division
[3] University Hospital Center Zagreb,UCSF Weill Institute for Neurosciences, Department of Neurology
[4] University of Zagreb,Department of Neurology
[5] School of Medicine,Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat)
[6] Moscow State Public Healthcare InsCity Clinical Hospital 24,undefined
[7] Research Institute of the McGill University Health Centre,undefined
[8] University of California San Francisco,undefined
[9] First Saint Petersburg State Medical University,undefined
[10] Novartis Pharmaceuticals Corporation,undefined
[11] Novartis Pharma B.V.,undefined
[12] Novartis Healthcare Private Limited,undefined
[13] Hospital Universitari Vall d’Hebron,undefined
[14] School of Public Health at Oregon Health and Science University,undefined
来源：
Neurology and Therapy | 2022年 / 11卷
关键词：
ALITHIOS; Anti-CD20 therapy; B-cell therapy; COVID-19; Ofatumumab; Post-marketing; Relapsing multiple sclerosis; SARS-CoV-2; Vaccination;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：741 / 758
页数：17
相关论文
共 50 条
  • [21] COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?
    Gelibter, Stefano
    Orrico, Mario
    Filippi, Massimo
    Moiola, Lucia
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 49
  • [22] Immune Response after COVID-19 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs
    Mazziotti, Valentina
    Crescenzo, Francesco
    Tamanti, Agnese
    Dapor, Caterina
    Ziccardi, Stefano
    Guandalini, Maddalena
    Colombi, Annalisa
    Camera, Valentina
    Peloso, Angela
    Pezzini, Francesco
    Turano, Ermanna
    Marastoni, Damiano
    Calabrese, Massimiliano
    BIOMEDICINES, 2022, 10 (12)
  • [23] Safety, immunogenicity, efficacy, and acceptability of COVID-19 vaccination in people with multiple sclerosis: a narrative review
    Capone, Fioravante
    Rossi, Mariagrazia
    Cruciani, Alessandro
    Motolese, Francesco
    Pilato, Fabio
    Di Lazzaro, Vincenzo
    NEURAL REGENERATION RESEARCH, 2023, 18 (02) : 284 - 288
  • [24] Ofatumumab for relapsing forms of multiple sclerosis
    Gajofatto, Alberto
    Orlandi, Riccardo
    DRUGS OF TODAY, 2022, 58 (01) : 9 - 21
  • [25] Vaccination in multiple sclerosis patients during the COVID-19 pandemic
    Brola, Waldemar
    Bielecka, Ewa
    AKTUALNOSCI NEUROLOGICZNE, 2021, 21 (03): : 137 - 142
  • [26] Clinical features and outcomes of COVID-19 despite SARS-CoV-2 vaccination in people with multiple sclerosis
    Rose, Deja R.
    Mahadeen, Khmad Z.
    Carlson, Alise K.
    Planchon, Sarah M.
    Sedlak, Jennifer
    Husak, Scott
    Bermel, Robert A.
    Cohen, Jeffrey A.
    Moss, Brandon P.
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2021, 7 (04)
  • [27] Vaccination and multiple sclerosis in the era of the COVID-19 pandemic
    Monschein, Tobias
    Hartung, Hans-Peter
    Zrzavy, Tobias
    Barnett, Michael
    Boxberger, Nina
    Berger, Thomas
    Chataway, Jeremy
    Bar-Or, Amit
    Rommer, Paulus Stefan
    Zettl, Uwe K.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2021, 92 (10) : 1033 - 1043
  • [28] The study of COVID-19 infection following vaccination in patients with multiple sclerosis
    Ghadiri, Fereshteh
    Sahraian, Mohammad Ali
    Azimi, Amirreza
    Moghadasi, Abdorreza Naser
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
  • [29] Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies
    Spierer, Ronen
    Lavi, Idit
    Bloch, Sivan
    Mazar, Marianna
    Golan, Daniel
    JOURNAL OF NEUROLOGY, 2023, 270 (10) : 4632 - 4639
  • [30] Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies
    Ronen Spierer
    Idit Lavi
    Sivan Bloch
    Marianna Mazar
    Daniel Golan
    Journal of Neurology, 2023, 270 : 4632 - 4639
12345